1- The University of Tabriz , moosav_m@tabrizu.ac.ir 2- The University of Tabriz 3- The Medical Science University of Tabriz
Abstract: (12472 Views)
ABSTRACT
Background and Aim: Leukemia is a malignant and progressive disorder in which genetic defects in hematopoietic cells lead to uncontrolled proliferation of blood cells. Different drugs have been proposed for the treatment of leukemia but none of them resulted in complete remission. Recently, anti-cancer effects of carbenoxolone (CBX), that is a 3-hemisuccinate, have been reported in several cell lines. In the present study we evaluated the effects of CBX on K562 cell line as an experimental model of chronic myeloid leukemia (CML).
Material and Methods: K562 cells were cultured and treated for various time intervals with different concentrations of CBX (50-300µM). Trypan blue exclusion test and tetrazolium salt absorption test (MTT) were used to evaluate the growth inhibitory and apoptotic effects of the drug. Fluorescence microscopy and DNA fragmentation assay were used to study apoptosis.
Results: The results of this study showed that CBX induced growth inhibition of K562 cells in a dose- and time- dependent manner. For example, growth inhibition rates after 48 hours treatment with concentrations of 50 µm, 100 µm, 150 µm, 200 µm and 300 µm were 11%, 41%, 59%, 79% and 92%, respectively. Furthermore results of fluorescence microscopy and DNA fragmentation assays indicated that apoptosis, is the cause of cell death induced by CBX.
Conclusion: Considering the growth inhibitory and apoptotic effects of CBX on human myeloid leukemia K562 cells, the drug can be considered as a potential candidate for further studies on CML treatment.
Key words: Apoptosis, Carbenoxolone, Leukemia, K562 cell line
Conflict of Interest: Nill
Received: July 28, 2010 Accepted: Dec 4, 2010
Moosavi S A, Moasses ghafary S, Asadi M, Asvadi-Kermani I. Growth inhibitory and apoptotic effects of carbenoxolone in human leukemia K562 cell Line. SJKU 2011; 16 (1) :27-37 URL: http://sjku.muk.ac.ir/article-1-465-en.html